drugset
drugset / Trial / NCT01111526

Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)

NCT01111526 ↗

Phase 1/2 Completed 22 enrolled H. Lee Moffitt Cancer Center and Research Institute Novartis · collab
NaSingle-groupOpen-labelTreatment

Summary

To test a new agent, LBH589, in combination with glucocorticoids as initial therapy of acute graft versus host disease (GVHD).

Timeline

Start
2010-04
Primary completion
2015-10
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Panobinostat Small molecule 1.25 mg/m2 Intravenous
Subject Panobinostat Small molecule 2.5 mg/m2 Intravenous
Subject Panobinostat Small molecule 5 mg/m2 Intravenous
Subject Panobinostat Small molecule 5 mg Intravenous
Subject Panobinostat Small molecule 7.5 mg/m2 Intravenous
Subject Panobinostat Small molecule 10 mg/m2 Intravenous
Subject Panobinostat Small molecule 10 mg Intravenous
Subject Panobinostat Small molecule 15 mg Intravenous
Subject Panobinostat Small molecule 20 mg Intravenous
Subject Panobinostat Small molecule 25 mg Intravenous

Indications

graft versus host disease